Tracey D. Arnell, MD

Ryan Lawrence joined the faculty in 2014 as an inpatient psychiatrist on 9 Garden North (Milstein Hospital). He then served as unit chief of 3 River East, a 30 bed MICA inpatient unit located at the Allen Hospital. He is currently the director of the Comprehensive Psychiatric Emergency Program at Columbia University Medical Center. His writing is focused on topics related to ethics and patient safety.

Dr. S. Sunghyun Yoon is the Chief of the Division of Surgical Oncology and Vice-Chair of Surgical Oncology Research and Education in the Department of Surgery at Columbia University Irving Medical Center (CUIMC). Dr. Yoon is a national and international expert in the treatment of patients with sarcomas and other soft tissue tumors, gastric (stomach) and gastroesophageal cancers, gastrointestinal stromal tumors (GISTs), and melanoma. He also has over 18 years of experience in the treatment of other gastrointestinal and abdominal tumors, hepatobiliary tumors, neuroendocrine/adrenal tumors, lymphomas, and spleen tumors. He has been the principal investigator of several clinical trials examining novel treatment strategies and given numerous invited national and international lectures in relation to these cancers. Several of these trials have investigated the treatment of sarcomas, especially abdominal/retroperitoneal sarcomas, with advanced radiation techniques such as proton beam radiation and aggressive surgical resection to minimize local recurrence. Read More About These Treatments: https://columbiasurgery.org/conditions-and-treatments/retroperitoneal-sarcomas-and-pelvic-sarcomas Dr. Yoon was an early advocate for minimally invasive robotic surgery and has performed over 300 robotic procedures including robotic gastrectomies (stomach removal). He has one of the world’s largest experiences in performing prophylactic total gastrectomies for patients with hereditary diffuse gastric cancer (HDGC syndrome) secondary to germline CDH1 mutation. He pioneered a technique for connection of the small bowel to the esophagus after total gastrectomy that is used by former surgical trainees and colleagues throughout the country due to its extremely low leakage rate. Dr. Yoon graduated from Harvard University and received his M.D. from the University of California at San Diego. He completed his residency in general surgery at Massachusetts General Hospital and his fellowship in surgical oncology at the Memorial Sloan-Kettering Cancer Center. He was an Associate Professor of Surgery at Massachusetts General Hospital and Harvard Medical School before joining the staff at Memorial Sloan-Kettering Cancer Center in 2012. Dr. Yoon was an Attending Surgeon in the Division of Gastric and Mixed Tumors at Memorial Sloan Kettering Cancer Center and a Professor of Surgery at Weill Cornell Medical College before joining CUIMC in 2021. Dr. Yoon’s main research interests are in cancer stem cells and targeted biological agents in combination with chemotherapy and radiation therapy. His laboratory has been funded by the National Institutes of Health/National Cancer Institute for 18 years and strives to translate new research discoveries into the clinic. Dr. Yoon is also part of multi-institution research groups funded by Stand Up To Cancer and the DeGregorio Family Foundation to discover early diagnostics and new therapies for gastric cancer. His clinical and research efforts have led to over 150 original research articles, book chapters, and reviews. For a complete list of publications, please visit NCBI.

Dr. Henick is a medical oncologist specializing in the care of patients with malignancies of the aerodigestive tract. As the Director of the HICCC Phase I Unit and Director of Translational Research in Aerodigestive Cancers in Medical Oncology, Dr. Henick’s clinical care and research are aligned to improve the effectiveness of, and limit side effects from, emerging cancer treatments. These efforts entail clinical trials that Dr. Henick has written and leads to study novel therapeutic approaches and to reduce steroid dependence among patients experiencing adverse events from immunotherapy.